Table 2 Seroconversion in 83 patients with hematological malignancies.
Disease | Patients |
|---|---|
B-cell lymphoproliferative disorders | 36/48 |
Chronic lymphocytic leukemia | 4/7 |
Indolent non-Hodgkin lymphoma | 18/25 |
Follicular lymphoma | 10/14 |
Marginal zone lymphoma | 4/6 |
MALT lymphoma | 0/1 |
Lymphoplasmacytic lymphoma | 3/3 |
Hairy-cell leukemia | 1/1 |
Aggressive non-Hodgkin lymphoma | 14/16 |
Diffuse large B-cell lymphoma | 9/10 |
Cutaneous B-cell lymphoma | 2/3 |
Burkitt lymphoma | 2/2 |
Mediastinal B-cell lymphoma | 1/1 |
Monoclonal gammopathies | 17/28 |
MGUS | 1/1 |
Smoldering multiple myeloma | 2/2 |
Active multiple myeloma | 14/25 |
Hodgkin lymphoma | 6/7 |
Treatment | |
Never received | 14/17 |
On | 6/17 |
Off | 39/49 |
Lines of therapy | |
1 | 35/44 |
2 or more | 10/22 |
Previous treatment | |
Anti-CD20 | 22/27 |
Anti-CD38 | 6/12 |
Immunomodulatory drugs | 11/22 |
Autologous stem cell transplantation | 14/20 |
Depth of response before vaccination in treated patients | |
Complete response | 54/66 |
No complete response | 12/66 |
